依达拉奉注射液联合丁苯酞软胶囊对颅内动脉粥样硬化性狭窄所致急性脑梗死的疗效

Efficacy of edaravone injection combined with butylphthalide soft capsules on acute cerebral infarction caused by intracranial atherosclerotic stenosis

目的观察依达拉奉注射液联合丁苯酞软胶囊治疗颅内动脉粥样硬化性狭窄(intracranial atherosclerotic stenosis,ICAS)所致急性脑梗死的临床效果。方法纳入63例伴有ICAS的急性脑梗死患者,随机分为观察组(n=32)和对照组(n=31)。对照组予抗血小板聚集、调脂稳定斑块、营养神经及改善循环等治疗,观察组在对照组基础上加用依达拉奉注射液,疗程14 d,丁苯酞软胶囊,疗程3个月。收集两组患者治疗前和治疗14 d时神经功能缺损评分(National Institute of Health stroke scale,NIHSS)、血清超敏C反应蛋白水平(high-sensitivity C-reactive protein,hs-CRP),治疗前改良Rankin量表(modified Rankin scale,mRS)评分,治疗后3个月时NIHSS评分和mRS评分,比较两组间的疗效差异。结果治疗后14 d及3个月,两组NIHSS均较治疗前下降,且观察组低于对照组(P<0.05)。治疗后3个月,观察组mRS评分较治疗前下降,且观察组低于对照组(P<0.05)。治疗后14 d,两组hs-CRP水平均较治疗前下降,且观察组低于对照组(P<0.05)。除观察组有1例一过性谷丙转氨酶轻度升高外,两组均未观察到其他不良反应,且未发生脑缺血事件。结论依达拉奉注射液联合丁苯酞软胶囊可以有效改善ICAS所致急性脑梗死患者的神经功能,降低血清hs-CRP。

Objective To observe the clinical effect of edaravone injection combined with butylphthalide soft capsules on acute cerebral infarction(ACI)caused by intracranial atherosclerotic stenosis(ICAS).Method A total of 63 ACI patients with ICAS were randomly divided into observation group(n=32)and control group(n=31).Treatment of antiplatelet aggregation,lipid regulation,stabilizing atherosclerotic plaque,nerve nourishment,and circulation improvement were given to the control group,while a 14-day course of edaravone injection and a 3-month course of butylphthalide soft capsules were added to the observation group based on the treatment given to the control group.National Institute of Health stroke scale(NIHSS)scores and serum levels of high-sensitivity C-reactive protein(hs-CRP)of both groups before and on 14th day of the treatment,modified Rankin scale(mRS)scores before treatment,as well as the NIHSS scores and mRS scores 3 months after treatment were collected,the efficacy difference between two groups were analyzed.Result After the 14-day and 3-month course of treatment,the NIHSS scores of both groups were lower than those before treatment,and the NIHSS scores of the observation group were lower than those of the control group(P<0.05).Three month after treatment,the mRS scores of the observation group were lower than those before treatment,and the mRS scores of the observation group were lower than those of the control group(P<0.05).Fourteen days after treatment,the level of hs-CRP in both groups were lower than that before treatment,and that in the observation group was lower than that in the control group(P<0.05).Except one case of transient slight alanine aminotransferase elevation was found in the observation group,no other adverse reactions were observed in either group,and no cerebral ischemia event occurred.Conclusion Edaravone injection combined with butylphthalide soft capsules could effectively improve neural function of ICAS patients caused by ACI and lower the level of serum hs-CRP.